We report the case of a 72-year-old woman who was diagnosed in 2006 with renal cell cancer (RCC) and had undergone consecutive tumor nephrectomy (clear-cell RCC, Fuhrmann grade II, stage pT3a, R0).
Over the years, the patient underwent several surgical and radiological interventions due to various metastatic lesions. This case report describes the 3-year progression-free survival in a patient who underwent first-line therapy with the monoclonal antibody bevacizumab. Except for hypertension, the patient does not suffer currently from any other side effects of bevacizumab therapy.
Der Urologe. Ausg. A. 2015 Oct 17 [Epub ahead of print]
R Pichler, W Horninger, F Aigner, I Heidegger
Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. Renate. Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. , Universitätsklinik für Radiologie, Medizinische Universität Innsbruck, Innsbruck, Österreich. , Universitätsklinik für Urologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich.